Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 26, 2025

Target vs. Costco: Which Discount Retail Stock Offers More Upside Now?

View original at finance.yahoo.com
Target vs. Costco: Which Discount Retail Stock Offers More Upside Now? Target Corporation TGT and Costco Wholesale Corporation COST are two of the most prominent names in the U.S…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Costco stands out as the stronger investment candidate, supported by its membership-based business model, high customer loyalty and consistent operational efficiency.

    80% confidence

  • The Zacks Consensus Estimate for Target's current fiscal-year EPS has declined 13 cents to $7.29 over the past 60 days.

    80% confidence

  • Digital initiatives are helping the company better monetize its product mix, particularly in non-food and big-ticket categories, while still enhancing and not replacing the in-store shopping experience.

    80% confidence

  • Target plans to increase capital expenditure 25% to $5 billion in fiscal 2026 to support store remodels, larger-format locations, expanded fulfillment and major floor-pad upgrades.

    80% confidence

  • The Zacks Consensus Estimate for Costco's current fiscal-year EPS has moved upward by 12 cents to $20.09 over the past 60 days.

    80% confidence

  • AI-driven pharmacy inventory systems helped lift in-stock levels and supported solid growth in prescription volumes.

    80% confidence

  • Both Target and Costco currently carry a Zacks Rank #3 (Hold).

    80% confidence

  • On-shelf availability for key items improved more than 150 basis points year over year, reflecting stronger inventory forecasting and in-stock execution.

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
Target vs. Costco: Which Discount Retail Stock Offers More Upside Now? — Source | Via News | ViaNews EU